Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/9/2024 | $60.00 | Outperform | Leerink Partners |
8/26/2024 | $65.00 | Peer Perform → Outperform | Wolfe Research |
4/22/2024 | $53.00 | Outperform | Oppenheimer |
2/15/2024 | Peer Perform | Wolfe Research | |
1/4/2024 | Neutral → Overweight | JP Morgan | |
1/3/2024 | $45.00 → $30.00 | Buy → Neutral | BofA Securities |
12/19/2023 | $26.00 | Overweight → Equal Weight | Wells Fargo |
6/30/2023 | $50.00 | Buy | Truist |
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13G - Kymera Therapeutics, Inc. (0001815442) (Subject)
SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
S-3ASR - Kymera Therapeutics, Inc. (0001815442) (Filer)
10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one-on-one meetings only;Stifel 2024 Healthcare Conference in New York, NY on November 18 at 11:30 a.m. ET;6th Annual Wolfe Research Healthcare Conference in New York, NY on November 19
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior program guidance Company to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1 with a partner Well-ca
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases Phase 1 healthy volunteer data expected to be reported in the first half of 2025 WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it recently initiated dosing in the Phase 1 clinical trial in the US e
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior program guidance Company to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1 with a partner Well-ca
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company's conference call will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the web
Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 (STAT3) oncology degrader programs presented at ASCO and EHA, with major responses in liquid and solid tumors; Phase 1a dose escalation studies expected to complete enrollment in second half of 2024 Well-capitalized with $702 million in cash as of June 30, 2024, and runway into the first half of 2
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio
Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and maintains $52 price target.
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Neutral and raises the price target from $31 to $36.
Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter Phase 1 clinical trial in the first half of 2025 IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in the first half of 2025 Company to hold virtual Immunology R&D Day webcast today at
WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company's emerging pipeline of high-value immunology programs, including new target disclosures, supporting preclinical data and timing to clinical study initiation. To join the webcast, please visit this link, or the "Events and Presentations" page of the Investors section on the Company'
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies. As a member of the Company's senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera's expanding pipeline. "At Kymera, we ha
Leerink Partners resumed coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $60.00
Wolfe Research upgraded Kymera Therapeutics from Peer Perform to Outperform and set a new price target of $65.00
Oppenheimer initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $53.00